Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, August 2025
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
For patients with non-severe COVID-19, we recommend not to use fluvoxamine, except in the context of a clinical trial
Recommended against
Strong
Notes and Remarks
Practical info The GDG made a recommendation against using fluvoxamine for treatment of patients with COVID-19 outside the setting of a clinical trial and therefore practical considerations are less relevant for this drug.
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 14 July 2022.
Year2022
InstitutionWHO
Guideline
Therapeutics and COVID-19: living guideline, 16 September 2022.
Year2022
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 13 January 2023.
Year2023
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 10 November 2023.
Year2023
InstitutionWorld Health Organization